UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000001012 |
|---|---|
| Receipt number | R000001177 |
| Scientific Title | A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01) |
| Date of disclosure of the study information | 2008/02/04 |
| Last modified on | 2022/08/30 17:32:54 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)
Acronym
A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)
Scientific Title
A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)
Scientific Title:Acronym
A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)
Region
| Japan | Asia(except Japan) |
Condition
Condition
clinical stage IV gastric cancer
Classification by specialty
| Gastroenterology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the survival benefit and safety of gastrectomy plus chemotherapy compared to chemotherapy alone in clinical stage IV gastric cancer with a single non-curable factor
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Phase III
Assessment
Primary outcomes
overall survival
Key secondary outcomes
progression-free survival, adverse events
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine | Maneuver |
Interventions/Control_1
A: Chemotherapy alone (S-1 80mg/m2 on days 1-21; CDDP 60mg/m2 on day 8, every 5 weeks)
Interventions/Control_2
B: Gastrectomy with D1 lymphadenectomy followed by chemotherapy (S-1 80mg/m2 on days 1-21; CDDP 60mg/m2 on day 8, every 5 weeks)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1) Histologically proven primary gastric adenocarcinoma.
2) Presence of distant metastases confined to either liver (H1), peritoneum (P1), or para-aortic lymphnode (16a1/b2), which is confirmed by both CT scan and laparotomy.
3) Clinical T1-3.
4) No other distant metastasis than H1, P1or M1(LN 16a1/b2).
5) No apparent pleural effusion.
6) Length of esophageal invasion 3cm or less with no need of thoracotomy for resection.
7) Aged 20 to 75 years old.
8) PS of 0 or 1.
9) Sufficient oral intake without active bleeding from the gastric tumor.
10) No prior treatment of chemotherapy or radiation therapy against any other malignancies, and no prior treatment for gastric cancer except EMR.
11) Adequate organ functions defined as indicated below
(1)WBC >= 3,000 /mm3 , WBC <= 12,000 /mm3
(2)Hb >= 8.0 g/dL without any transfusion 2 weeks before enrollment
(3)Plt >= 100,000 /mm3
(4)AST <= 100 IU/L
(5)ALT <= 100 IU/L
(6)T.Bil <= 2.0 mg/dL
(7)Cr <= 1.2 mg/dL
(8)Ccr >= 60 mL/min/body
12) Written informed consent
Key exclusion criteria
1) Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment.
2) Women during pregnancy or breast-feeding.
3) Psychosis.
4) Systemic steroids medication.
5) Medication of furucytocin, fenytoin, or warfarin.
6) Active bacterial infection or mycosis, affecting systemic condition.
7) Myocardial infarction or unstable angina, occurred within 6 months.
8) Uncontrollable hypertension.
9) Uncontrollable diabetes mellitus or administration of insulin.
10) Pulmonary disease necessitating continuous oxygen supply.
Target sample size
330
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Toshimasa Tsujinaka |
Organization
National Hospital Organization Osaka National Hospital
Division name
Department of Surgery
Zip code
Address
2-1-14, Hoenzaka, Chuo-ku, Osaka, Osaka 540-0006, Japan
TEL
06-6942-1331
JCOG_sir@ml.jcog.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Kazumasa Fujitani |
Organization
JCOG0705 Coordinating Office
Division name
National Hospital Organization Osaka National Hospital, Department of Surgery
Zip code
Address
2-1-14, Hoenzaka, Chuo-ku, Osaka, Osaka 540-0006, Japan
TEL
06-6942-1331
Homepage URL
http://www.jcog.jp/
JCOG_sir@ml.jcog.jp
Sponsor or person
Institute
Japan Clinical Oncology Group (JCOG)
Institute
Department
Personal name
Funding Source
Organization
Ministry of Health, Labour and Welfare
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
函館厚生院函館五稜郭病院（北海道）
岩手医科大学 （岩手県）
国立病院機構仙台医療センター（宮城県）
宮城県立がんセンター （宮城県）
山形県立中央病院 （山形県）
栃木県立がんセンター（栃木県）
防衛医科大学校 （埼玉県）
埼玉県立がんセンター（埼玉県）
国立がん研究センター東病院（千葉県）
国立がん研究センター中央病院 （東京都）
がん・感染症センター都立駒込病院 （東京都）
東京医科歯科大学 （東京都）
がん研究会有明病院 （東京都）
虎の門病院（東京都）
都立墨東病院 （東京都）
神奈川県立病院機構神奈川県立がんセンター （神奈川県）
北里大学医学部（神奈川県）
横浜市立大学附属市民総合医療センター（神奈川県）
新潟県立がんセンター新潟病院 （新潟県）
新潟県厚生連長岡中央綜合病院 （新潟県）
燕労災病院 （新潟県）
富山県立中央病院 （富山県）
石川県立中央病院（石川県）
岐阜大学医学部（岐阜県）
岐阜市民病院 （岐阜県）
静岡県立総合病院 （静岡県）
静岡県立静岡がんセンター（静岡県）
愛知県がんセンター中央病院 （愛知県）
名古屋大学医学部（愛知県）
藤田保健衛生大学 （愛知県）
国立病院機構京都医療センター（京都府）
京都第2赤十字病院 （京都府）
大阪大学医学部（大阪府）
近畿大学医学部 （大阪府）
大阪府立病院機構大阪府立成人病センター （大阪府）
国立病院機構大阪医療センター （大阪府）
大阪医科大学 （大阪府）
市立豊中病院 （大阪府）
市立堺病院 （大阪府）
関西医科大学附属枚方病院（大阪府）
神戸大学医学部（兵庫県）
関西労災病院（兵庫県）
兵庫医科大学（兵庫県）
兵庫県立がんセンター（兵庫県）
市立伊丹病院 （兵庫県）
天理よろづ相談所病院（奈良県）
和歌山県立医科大学 （和歌山県）
島根大学医学部（島根県）
広島市立広島市民病院 （広島県）
広島市立安佐市民病院（広島県）
福山市民病院（広島県）
国立病院機構四国がんセンター（愛媛県）
高知医療センター（高知県）
大分大学医学部附属病院（大分県）
Other administrative information
Date of disclosure of the study information
| 2008 | Year | 02 | Month | 04 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
http://www.ncbi.nlm.nih.gov/pubmed/26822397
Number of participants that the trial has enrolled
Results
See the datails via "URL releasing results" above.
Also the details can be seen in the JCOG website:
http://www.jcog.jp/en/trials/index.html
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2007 | Year | 12 | Month | 18 | Day |
Date of IRB
| 2008 | Year | 02 | Month | 01 | Day |
Anticipated trial start date
| 2008 | Year | 02 | Month | 01 | Day |
Last follow-up date
| 2014 | Year | 02 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2008 | Year | 02 | Month | 04 | Day |
Last modified on
| 2022 | Year | 08 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001177
